GHP Investment Advisors Inc. raised its holdings in Laboratory Corp. of America Holdings (NYSE:LH) by 12.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,627 shares of the medical research company’s stock after purchasing an additional 1,447 shares during the quarter. GHP Investment Advisors Inc.’s holdings in Laboratory Corp. of America were worth $2,014,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in LH. Boston Partners lifted its stake in shares of Laboratory Corp. of America by 13.9% in the 4th quarter. Boston Partners now owns 5,264,025 shares of the medical research company’s stock valued at $839,665,000 after acquiring an additional 644,355 shares during the last quarter. Bridger Management LLC bought a new position in shares of Laboratory Corp. of America in the 4th quarter valued at $100,996,000. JPMorgan Chase & Co. lifted its stake in shares of Laboratory Corp. of America by 57.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,350,903 shares of the medical research company’s stock valued at $202,298,000 after acquiring an additional 492,866 shares during the last quarter. Check Capital Management Inc. CA lifted its stake in shares of Laboratory Corp. of America by 95.2% in the 3rd quarter. Check Capital Management Inc. CA now owns 526,500 shares of the medical research company’s stock valued at $79,486,000 after acquiring an additional 256,802 shares during the last quarter. Finally, PGGM Investments lifted its stake in shares of Laboratory Corp. of America by 254.1% in the 4th quarter. PGGM Investments now owns 293,200 shares of the medical research company’s stock valued at $46,768,000 after acquiring an additional 210,408 shares during the last quarter. Institutional investors own 92.44% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other news, Director Adam H. Schechter sold 1,263 shares of Laboratory Corp. of America stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $169.29, for a total value of $213,813.27. Following the completion of the transaction, the director now directly owns 7,297 shares of the company’s stock, valued at approximately $1,235,309.13. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Glenn A. Eisenberg sold 8,400 shares of Laboratory Corp. of America stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $167.36, for a total value of $1,405,824.00. Following the completion of the transaction, the chief financial officer now directly owns 15,931 shares of the company’s stock, valued at $2,666,212.16. The disclosure for this sale can be found here. 0.90% of the stock is owned by company insiders.

Laboratory Corp. of America Holdings (NYSE LH) opened at $174.65 on Wednesday. The stock has a market capitalization of $17,894.66, a price-to-earnings ratio of 14.30, a P/E/G ratio of 1.48 and a beta of 0.90. The company has a current ratio of 1.31, a quick ratio of 1.20 and a debt-to-equity ratio of 0.93. Laboratory Corp. of America Holdings has a 12-month low of $134.19 and a 12-month high of $181.71.

Laboratory Corp. of America (NYSE:LH) last announced its earnings results on Tuesday, February 6th. The medical research company reported $2.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.38 by $0.07. The business had revenue of $2.70 billion during the quarter, compared to analyst estimates of $2.70 billion. Laboratory Corp. of America had a return on equity of 16.30% and a net margin of 12.15%. Laboratory Corp. of America’s revenue for the quarter was up 13.2% compared to the same quarter last year. During the same period last year, the company earned $2.15 EPS. equities research analysts anticipate that Laboratory Corp. of America Holdings will post 11.54 earnings per share for the current year.

A number of brokerages have recently commented on LH. Credit Suisse Group reiterated an “outperform” rating and issued a $195.00 price target (up from $192.00) on shares of Laboratory Corp. of America in a research note on Thursday, March 8th. Jefferies Group reiterated a “hold” rating and issued a $176.00 price target on shares of Laboratory Corp. of America in a research note on Tuesday, March 6th. ValuEngine cut Laboratory Corp. of America from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Citigroup increased their price target on Laboratory Corp. of America from $161.00 to $184.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Finally, Goldman Sachs Group began coverage on Laboratory Corp. of America in a research note on Monday, January 29th. They issued a “buy” rating and a $205.00 price target for the company. Six analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $188.33.

WARNING: This report was originally reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2018/03/14/laboratory-corp-of-america-holdings-lh-shares-bought-by-ghp-investment-advisors-inc.html.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.